A new lung cancer drug that disrupts blood vessels within the tumor and inhibits blood flow to it looks promising, say researchers who are slated to report their findings Thursday at a cancer meeting in California.
When added to traditional chemotherapy, the new drug, called vadimezan and also known as ASA404 or DMXAA, extended survival time, says Mark McKeage, PhD, an associate professor in clinical pharmacology at the University of Auckland, New Zealand, who is presenting the findings at the American Association for Cancer Research — International Association for the Study of Lung Cancer meeting in Coronado, Calif.
Biosingularity 
Regardless of your individual treatment plan, know that modifications can be made, before, during, and after your treatment, to help you best manage your therapy course and any side effects that come your way. Talking with your doctor about any potential issues, and addressing issues as they arise, is an important first step.